Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

July 1, 2013

Primary Completion Date

September 20, 2016

Study Completion Date

October 6, 2017

Conditions
HER2-mutant Non-Small Cell Lung Cancer
Interventions
DRUG

neratinib

DRUG

temsirolimus

Trial Locations (21)

10065

Memorial Sloan-Kettering Cancer Center, New York

13915

Hopital Nord, Marseille

15232

University of Pittsburgh Cancer Institute, Pittsburgh

21231

Johns Hopkins, Baltimore

30030

CHU de Toulous Hopital Larre, Toulouse

33612

Moffitt Cancer Center, Tampa

37232

Vanderbilt University, Nashville

38043

CHU de Grenoble Hopital Albert Michallon, Grenoble

43210

Ohio State University, Columbus

59037

CHRU de Lille - Hopital Calmette, Lille

63110

Washington University School of Medicine, St Louis

75390

UT Southwestern Medical Center, Dallas

77030

MD Anderson Cancer Center, Houston

80045

University of Colorado, Aurora

91010

City of Hope, Duarte

94040

University of California Los Angeles, Santa Monica

94805

Institut Gustave Roussy, Villejuif

167091

Hopitaux universitaires de Strasbourg Nouvel Hopital Civil, Strasbourg

02215

Beth Israel Deaconess Medical Center, Boston

Dana Farber Cancer Institute, Boston

Massachusettes General Hospital, Boston

All Listed Sponsors
lead

Puma Biotechnology, Inc.

INDUSTRY

NCT01827267 - Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter